The estimated Net Worth of Ventures Fund V General Par... is at least 17.2 百万$ dollars as of 27 October 2020. Ventures Par owns over 150,000 units of Foghorn Therapeutics stock worth over 17,166,195$ and over the last 4 years Ventures sold FHTX stock worth over 0$.
Sign up
Ventures Par FHTX stock SEC Form 4 insiders trading
Ventures has made over 1 trades of the Foghorn Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Ventures bought 150,000 units of FHTX stock worth 2,400,000$ on 27 October 2020.
The largest trade Ventures's ever made was buying 150,000 units of Foghorn Therapeutics stock on 27 October 2020 worth over 2,400,000$. On average, Ventures trades about 150,000 units every 0 days since 2020. As of 27 October 2020 Ventures still owns at least 1,851,801 units of Foghorn Therapeutics stock.
You can see the complete history of Ventures Par stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Foghorn Therapeutics
Over the last 4 years, insiders at Foghorn Therapeutics have traded over 262,160$ worth of Foghorn Therapeutics stock and bought 305,500 units worth 4,888,000$ . The most active insiders traders include Adam Koppel、Ian F Smith、B Lynne Parshall. On average, Foghorn Therapeutics executives and independent directors trade stock every 109 days with the average trade being worth of 663,343$. The most recent stock trade was executed by Steven F. Bellon on 9 September 2024, trading 20,000 units of FHTX stock currently worth 190,000$.
What does Foghorn Therapeutics do?
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
What does Foghorn Therapeutics's logo look like?
Complete history of Ventures Par stock trades at Foghorn Therapeutics
Foghorn Therapeutics executives and stock owners
Foghorn Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Carl Peter Decicco Ph.D.,
Chief Scientific Officer -
Adrian H. B. Gottschalk,
Pres, CEO & Director -
Dr. Samuel Agresta M.D., M.P.H.,
Chief Medical Officer -
Dr. Cigall Kadoch Ph.D.,
Founder & Director -
Michael J. LaCascia,
Chief Legal Officer -
Dr. Douglas G. Cole M.D.,
Founder & Chairman -
Ben Strain,
VP of Investor Relations & Corp. Communications -
Dr. Gerald R. Crabtree M.d.,
Founder & Member of Scientific Advisory Board -
Dr. Steven F. Bellon Ph.D.,
Sr. VP of Drug Discovery -
Carlos Costa,
Sr. VP, People & Organization -
Dr. Allan Reine,
Chief Financial Officer -
Dr. Gerald R. Crabtree,
Founder & Member of Scientific Advisory Board -
Thomas J. Jr. Lynch,
-
B Lynne Parshall,
-
Dhabi Investment Authority ...,
-
Fanny Cavalie,
Chief Strategy/Bus Ops Officer -
Pioneering Inc.Flagship Pio...,
-
Ventures Fund V General Par...,
-
Anna Rivkin,
Chief Business Officer -
Michael Mendelsohn,
-
Ian F Smith,
-
Kristian Humer,
Chief Financial Officer -
Scott Biller,
-
Cigall Kadoch,
-
Simba Gill,
-
Douglas G. Cole,
-
Adam Koppel,
-
Allan Reine,
Chief Financial Officer -
Steven F. Bellon,
Chief Scientific Officer -
Michael La Cascia,
Chief Legal Officer -
Samuel Agresta,
Chief Medical Officer -
Carl Decicco,
Chief Scientific Officer -
Carlos Costa,
Chief People Officer -
Alfonso Quintas Cardama,
Chief Medical Officer